Quantcast
Last updated on April 19, 2014 at 6:57 EDT

Latest dacarbazine Stories

2010-11-30 22:03:38

Rush University Medical Center enrolls first US patient Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments. Rather than blocking or killing all rapidly dividing cells, whether malignant or not, the drug, called nilotnib, is one of a new class of agents that have been designed to sabotage...

2010-08-26 14:00:17

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in the August 26 New England Journal of Medicine. "Metastatic melanoma has a devastating prognosis and is one of the top causes of cancer death in young patients," says Keith...

2009-05-11 00:08:05

Therapies are in the pipeline for stage IV metastatic melanoma, the illness Dr. Izzie Stevens faces in the ABC drama Grey's Anatomy, a U.S. researcher said. Dermatologist Dr. Gary Rogers of Tufts University School of Medicine in Boston said in stage IV melanoma the tumor has spread to a distant site and the remission rate for a drug used to treat advanced melanoma -- dacarbazine -- is 10 percent. No studies to date show that chemotherapy or any treatment regimens are effective when melanoma...

2009-01-19 07:00:00

Ipilimumab Will Earn Decision Resources' Clinical Gold Standard for Stage IV Malignant Melanoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug for treating stage IV malignant melanoma that can increase median overall survival when compared with standard of care dacarbazine (Bedford Laboratories' DTIC-Dome,...

2008-12-03 05:30:00

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced an exclusive, binding letter of intent with EIP Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and marketing of the company's Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish Republic of Northern Cyprus. EIP has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price in...

2008-10-06 09:00:57

Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company's ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, Genta's lead oncology product, in patients with advanced melanoma. A pooled analysis of data from this study, which remains blinded, was compared with the Company's previous data from a similarly designed randomized trial. The comparative analysis shows that to date AGENDA has enrolled patients with similar demographics, and...

2008-09-16 12:00:49

Bristol-Myers Squibb Company and Medarex have announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma who had previously been treated. Study results show that approximately half of patients who received ipilimumab (10mg/kg) remained alive beyond one year. The results are based on follow-up of the patient population from studies 008, 022 and 007 treated with 10mg/kg of ipilimumab (induction and maintenance) and show a consistent...

2008-09-15 12:00:09

Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who had previously been treated. Study results show that approximately half of patients who received ipilimumab (10 mg/kg) remained alive beyond one year. The results are based on follow-up of the patient population from studies 008, 022 and 007 treated with 10 mg/kg of...

2008-09-11 09:00:09

AmpliMed, a cancer therapeutics company, has entered into a license agreement with Korean-based pharmaceutical company Handok Pharmaceuticals for exclusive rights to its investigational cancer therapeutic Amplimexon in Korea. Under terms of the agreement, Handok will receive marketing and distribution rights to all cancer indications for Amplimexon in Korea and will pay AmpliMed an up-front fee plus additional payments based upon the achievement of certain development and regulatory...